Anti-tumor effects of vascular endothelial growth factor fusion protein vaccine modified by a molecular adjuvant
10.13699/j.cnki.1001-6821.2017.13.016
- VernacularTitle:分子佐剂修饰的血管内皮生长因子融合蛋白疫苗抗肿瘤活性研究
- Author:
Lin GUO
1
;
Mei-Yu LU
;
Ling ZHOU
;
Min LI
;
Yu-Wei LIU
;
Bin-Lian DU
;
Qing-Shou YAO
;
Mao-Lei XU
Author Information
1. 滨州医学院葡萄酒学院
- Keywords:
vascular endothelial growth factor;
microbial heat shock protein 70;
molecular adjuvant;
recombined protein vaccine;
hepatocellular carcinoma
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(13):1225-1228
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate whether 2 repeats of mycobacterial microbial hot shock protein 70 (HSP70) 407-426 (2mHSP70407-426,M2) could act as an effective molecular adjuvant to enhance the anti-tumor efficiency of vascular endothelial growth factor (VEGF) fusion protein vaccine.Methods The gene encoding two tandem repeat sequences of HSP70407-426 was introduced to the terminus of the constructed hVEGF121 mutant 1 gene to prepare a recombined hVEGF121 mutant 2 protein vaccine by PCR technique.The anti-tumor efficacy of hVEGF121 mutant 2 protein vaccine was investigated using a H22 liver cancer subcutaneous tumor model.The 24 mice were randomly divided into three groups:model group,experiment 1 group (80 μg hVEGF121 mutant 1 protein) and experiment 2 group (80 μg hVEGF121 mutant 2 protein).The humoral and cellular immune responses were detected by ELISA and splenic lymphocyte proliferation assay.The anti-angiogenesis effect was evaluated by an intradermal tumor model.Results The tumor weight of the experimental 1 group and the experimental 2 group were (1.17± 0.25) g and (1.58 ± 0.28) g.Compared with the experimental 1 group,the tumor weight of tumor bearing mice in the experimental 2 group was lower significanfly(P ＜0.05).The anti-VEGF antibodies of the experimental 1 group and experimental 2 group was 0.54 ± 0.09,0.74 ± 0.1.Compared with experimental 1 group,higher titers of anti-VEGF antibody were detected in immune serum of the experimental 2 group with statistically significant(P ＜0.05).The proliferative activity of spleen lymphocytes in the experimental 1 group and the experimental 2 group was 0.26 ±0.03,0.36 ±0.04.Compared with the experimental 1 group,the vaccine immunization in experimental 2 group can stimulate the proliferation of spleen lymphocytes more effectively with statistically significant (P ＜ 0.05).Conclusion M2 could act as an effective adjuvant to help VEGF fusion protein vaccine to elicit a strong anti-tumor efficacy.
